Back

Implications of the 2021 CKD-EPI cystatin C/creatinine eGFR equation for eligibility for therapy in HFrEF: Insights from PARADIGM-HF

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Chronic heart failure - The kidney and heart failure Heart Failure with Reduced Ejection Fraction (HFrEF) ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Paolo Tolomeo

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)

7 More presentations in this session

Presentation thumbnail
Predicting the long-termoutcome of patients admitted with acute heart failure to the emergency department using renal markers
Doctor J. Borges-Rosa (Coimbra, PT)
Abstract Slides
Presentation thumbnail
Prognostic value of estimating appendicular muscle mass in heart failure using creatinine/cystatin C
Doctor T. Sunayama (Tokyo, JP)
Abstract Slides
Presentation thumbnail
Clinical impact of chronic kidney disease on appendicular skeletal muscle mass and mortality in hospitalized patients with acute heart failure
Mr E. Akiyama (Saitama, JP)
Abstract Slides
Presentation thumbnail
Causes of death in patients with chronic kidney disease: Insights from the ASCEND-D and ASCEND-ND cardiovascular outcomes trials
Professor A. Singh (Boston, US)
Abstract Slides
Presentation thumbnail
Incidence of heart failure and renal endpoints in heart failure patients with and without severe chronic kidney disease: a nationwide real-life study of 21,959 patients
Miss D. Zahir (Copenhagen, DK)
Abstract Slides

Access the full session

Session thumbnail
Chronic heart failure - The kidney and heart failure

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: a phenomics approach.
thumbnail
Congress Presentation
Clinical characteristics and long-term prognosis of patients with heart failure with reduced, mildly reduced, and preserved left ventricular ejection fraction secondary to Chagas cardiomyopathy
thumbnail
Congress Session
Meet the Experts: summation of the science - treatment of chronic heart failure in 2023

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources